Medical Devices
Advisory panel OKs Abbott's new cardiac device
An advisory panel to the Food and Drug Administration voted in favor of a new device from Abbott meant to treat patients with tricuspid heart valve disease, STAT's Lizzy Lawrence reports. All but one of the 14 panelists said the treatment's benefits outweighed its risks. The FDA tends to follow advisory panel recommendations.
The device is called the TriClip, and it addresses a disease called tricuspid regurgitation: a heart condition that causes blood to leak backward through the tricuspid heart valve. The condition impacts 1.6 million people in the United States. Symptoms include fatigue, swelling, and atypical heart rhythms. In severe cases, the condition can lead to heart failure.
Read more here
Lizzy's Device Digest
Robotic and traditional knee replacements have same reoperation rates, study finds
Robotic surgery may help with precision and efficiency — but does it actually lead to better operations? Lizzy tells us that a study presented at the American Academy of Orthopedic Surgeons on Monday shed some doubt on robotic surgery outcomes: researchers found that surgical revision rates in total knee replacements did not differ significantly between robotic and traditional approaches.
Researchers used the American Joint Replacement Registry to compare follow-up surgical rates between the two groups, ultimately identifying 9,220 patients. Around 45% of those patients underwent surgical procedures. "We found there was no significant differences in the risk of needing another operation within the first two years after surgery with a robotic-assisted or manual technique," Johns Hopkins surgeon and researcher Lucas E. Nikkel said in a press statement.
No comments